Histologic parameter | Endometrioid endometrial carcinoma | Non-endometrioid endometrial carcinoma | p chi-square test |
---|---|---|---|
Tumour differentiation | |||
G1 | 125 (59.2%) | 2 (13.3%) | |
G2 | 63 (29.9%) | 4 (26.6%) | |
G3 | 23 (10.9%) | 9 (60.0%) | |
Myometrial invasion | |||
none | 8 (3.8%) | 1 (6.3%) | |
less than ½ | 123 (58.3%) | 9 (56.2%) | |
more than ½ | 80 (37.9%) | 6 (37.5%) | |
2009 FIGO stage | |||
IA | 114 (54.0%) | 7 (43.8%) | |
IB | 54 (25.6%) | 1 (6.3%) | |
II | 14 (6.6%) | 2 (12.5%) | |
IIIA | 7 (3.3%) | 1 (6.3%) | |
IIIB | 5 (2.4%) | 0 (0.0%) | |
IIIC1 | 11 (4.7%) | 2 (12.5%) | |
IIIC2 | 0 (0.0%) | 0 (0.0%) | |
IVA | 1 (0.5%) | 1 (6.3%) | |
IVB | 5 (2.4%) | 2 (12.5%) |
Stage 1 | HSC (N = 117) | D&C (N = 59) | P value |
---|---|---|---|
Histologic type | |||
endometrioid adenocarcinoma | 112 (95.7%) | 56 (94.9%) | 0.807 chi-square test |
non-endometrioid adenocarcinoma | 5 (4.3%) | 3 (5.1%) | |
Tumour differentiation | |||
G1 | 75 (64.1%) | 29 (49.2%) | 0.156 chi-square test |
G2 | 32 (27.4%) | 22 (37.3%) | |
G3 | 10 (8.5%) | 8 (13.5%) | |
Myometrial invasion | |||
none | 5 (4.3%) | 3 (5.1%) | 0.079 chi-square test |
less than ½ | 71 (60.7%) | 45 (76.2%) | |
more than ½ | 41 (35.0%) | 11 (18.6%) | |
Peritoneal cytology positive or suspicious negative | 15 (12.8%) 102 (87.2%) | 2 (3.4%) 57 (96.6%) | chi-square test |
Time from diagnosis to operation (days) | 35.6 ± 14.0 | 33.1 ± 12.7 | 0.255 independent sample t-test |
Histologic parameter | HSC (N = 144) | D&C (N = 83) | P value | |
---|---|---|---|---|
Histologic type | ||||
endometrioid adenocarcinoma | 137 (95.1%) | 74 (89.2%) | 0.090 chi-square test | |
non-endometrioid adenocarcinoma | 7 (4.9%) | 9 (10.8%) | ||
Tumour differentiation | ||||
G1 | 90 (62.5%) | 37 (45.1%) | chi-square test | |
G2 | 40 (27.8%) | 27 (32.9%) | ||
G3 | 14 (9.7%) | 18 (22.0%) | ||
Myometrial invasion | ||||
none | 5 (3.5%) | 4 (4.8%) | 0.726 chi-square test | |
less than ½ | 82 (56.9%) | 50 (60.2%) | ||
more than ½ | 57 (39.6%) | 29 (34.9%) | ||
Lymphovascular invasion | ||||
present | 20 (13.9%) | 14 (16.9%) | chi-square test | |
absent | 124 (86.1%) | 69 (83.1%) | ||
2009 FIGO stage | ||||
IA | 75 (52.1%) | 46 (55.4%) | ||
IB | 42 (29.2%) | 13 (15.7%) | ||
II | 10 (6.9%) | 6 (7.2%) | ||
IIIA | 1 (0.7%) | 7 (8.4%) | ||
IIIB | 3 (2.1%) | 2 (2.4%) | chi-square test | |
IIIC1 | 9 (6.3%) | 4 (4.8%) | ||
IIIC2 | 0 (0.0%) | 0 (0.0%) | ||
IVA | 1 (0.7%) | 1 (1.2%) | ||
IVB | 3 (2.1%) | 4 (4.8%) | ||
Peritoneal cytology positive or suspicious negative | 19 (13.2%) 125 (86.8%) | 10 (12.0%) 73 (88.0%) | 0.803 chi-square test | |
Time from diagnosis to operation (days) | 35.8 ± 13.8 | 32.8 ± 15.4 | 0.140 independent sample t-test |